Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Wound Repair Regen ; 28(4): 517-525, 2020 07.
Article in English | MEDLINE | ID: mdl-32141182

ABSTRACT

High-dose folic acid (HDFA; vitamin B9)-5 mg, given daily, has not been evaluated as a treatment to improve early stage-diabetic foot ulcer (ES-DFU) wound healing. However, HDFA has been demonstrated to correct: (a) endothelial dysfunction and decreased nitric oxide (NO) bioavailability, associated with type-2 diabetes mellitus (T2DM); and (b) hyperhomocysteinemia (HHcy) that may promote impaired DFU-wound healing. Measures of wound area (cm2 ) reduction (wound closure; WC), over a 4-week period (4 W-WC), greater than 50% of the wound area, have been reported as a robust indicator of the potential for DFU-wound healing. By using this model, we examined the effectiveness of a wound treatment in promoting progressive healing and complete wound closure for the chronic, nonhealing DFU-wound. To investigate this possible relationship between HDFA and ES-DFU wound healing, a retrospective cohort study of medical records, between November 2018 and April 2019, was performed for Veterans with T2DM and ES-DFUs following treatment with HDFA. During the study period 29 (n = 29) Veterans with ES-DFU wounds who received HDFA treatment were identified. Medical record reviews of this retrospective cohort of ES-DFU Veterans receiving HDFA report 90% (26/29) experiencing complete DFU-wound closure during the study period. Of the 29 Veterans with ES-DFUs receiving HDFA, the medical records of nine (30%), with healed wounds, provided documentation suitable for 4 W-WC, pre- and post-HDFA treatment study comparisons. This study documents significant (P < .05) improvements comparing 4 W-WC values for standard treatment for Veterans with poorly progressing, worsening or stagnating ES-DFU-wounds to those for the same subjects following HDFA treatment. These observations suggest that chronic ES-DFUs treated with HDFA may experience significantly improved wound closure and complete healing (re-epithelialization) when compared with standard treatments without HDFA. With validation from RCTs, HDFA may be established as an effective treatment to promote wound healing and closure for nonhealing ES-DFUs.


Subject(s)
Diabetes Mellitus, Type 2/complications , Diabetic Foot/drug therapy , Folic Acid/administration & dosage , Vitamin B Complex/administration & dosage , Wound Healing , Aged , Aged, 80 and over , Diabetic Foot/etiology , Female , Humans , Male , Middle Aged , Re-Epithelialization , Retrospective Studies , Veterans
2.
J Diabetes Res ; 2016: 1586927, 2016.
Article in English | MEDLINE | ID: mdl-27840833

ABSTRACT

Diabetes mellitus is associated with chronic diabetic foot ulcers (DFUs) and wound infections often resulting in lower extremity amputations. The protein signaling architecture of the mechanisms responsible for impaired DFU healing has not been characterized. In this preliminary clinical study, the intracellular levels of proteins involved in signal transduction networks relevant to wound healing were non-biasedly measured using reverse-phase protein arrays (RPPA) in keratinocytes isolated from DFU wound biopsies. RPPA allows for the simultaneous documentation and assessment of the signaling pathways active in each DFU. Thus, RPPA provides for the accurate mapping of wound healing pathways associated with apoptosis, proliferation, senescence, survival, and angiogenesis. From the study data, we have identified potential diagnostic, or predictive, biomarkers for DFU wound healing derived from the ratios of quantified signaling protein expressions within interconnected pathways. These biomarkers may allow physicians to personalize therapeutic strategies for DFU management on an individual basis based upon the signaling architecture present in each wound. Additionally, we have identified altered, interconnected signaling pathways within DFU keratinocytes that may help guide the development of therapeutics to modulate these dysregulated pathways, many of which parallel the therapeutic targets which are the hallmarks of molecular therapies for treating cancer.


Subject(s)
Diabetic Foot/metabolism , Keratinocytes/metabolism , Signal Transduction/physiology , Skin/metabolism , Wound Healing/physiology , Aged , Apoptosis/physiology , Cell Proliferation/physiology , Diabetic Foot/pathology , Female , Humans , Keratinocytes/pathology , Male , Middle Aged , Neovascularization, Physiologic/physiology , Skin/pathology
3.
Am J Med Genet C Semin Med Genet ; 133C(1): 48-56, 2005 Feb 15.
Article in English | MEDLINE | ID: mdl-15645524

ABSTRACT

Several lines of evidence support the idea that individuals who commit suicide have a certain biological predisposition, part of which is given by genes. Studies investigating genetic factors increasing suicide predisposition have been limited by current knowledge of the suicide neurobiology and have typically investigated one or a few genes at a time, whereas it is anticipated that several genes account for the total genetic variance mediating suicide. This review focuses on the advantages and the interest of using the microarray technology to investigate the neurobiology of suicide and discusses, by means of a data analysis example, the possible methodological problems and bioinformatic strategies that should be employed in order to separate the signal from the large amount of background noise, which is usually generated in such studies. Microarray expression studies and related platforms are promising tools to gain better insight into the neurobiology of suicide.


Subject(s)
Brain/metabolism , Genetics, Medical/methods , Neurobiology/methods , Oligonucleotide Array Sequence Analysis/methods , Suicide , Brain/pathology , Cluster Analysis , Computational Biology/methods , Genetic Predisposition to Disease/genetics , Humans , Principal Component Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...